Psilocybin: Systematic review of its use in the treatment of depression
European Psychiatry – April 01, 2025
Source: OpenAlex
Summary
Psilocybin, a potent psychedelic compound, offers rapid and sustained relief for depressive symptoms, even in treatment-resistant cases. A systematic review of drug studies published between 2019 and 2024, focusing on this alkaloid, revealed significant improvements compared to standard treatments. Often derived through chemical synthesis, psilocybin provides symptomatic relief with fewer treatment sessions and a favorable safety profile. This suggests a promising new direction in psychedelics and drug studies for mental health.
Abstract
Introduction Psilocybin, a psychedelic compound, has shown potential in treating depression, especially in cases resistant to conventional treatments. This study systematically reviews the scientific literature to assess its efficacy and safety. Objectives The main objective of this study is to evaluate the therapeutic effects of psilocybin for the treatment of depressive disorder through a systematic review of the current scientific literature Methods An exhaustive search was conducted in databases such as PubMed and Web of Science, using specific MeSH term and selecting studies published between 2019-2024 that investigated the effects of psilocybin in treating depression. Results The included studies demonstrated significant improvements in depressive symptoms with psylocibin compared to standard treatments. Studies reports a rapid and sustained symptom reduction, with few adverse effects. Conclusions Psilocybin could be an effective and safe alternative for treating depression, providing symptomatic relief with fewer treatment sessions and a favorable safety profile. However, further research is needed to overcome current limitations and fully understand its therapeutic potential and underlying mechanisms. Disclosure of Interest None Declared